The effectiveness of eugenol against cisplatin-induced ototoxicity
Copyright © 2018 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. All rights reserved..
INTRODUCTION: Ototoxicity refers to cellular damage or function impairment developing in the inner ear in association with any therapeutic agent or chemical substance, and still represents the principal side-effect restricting the use of cisplatin.
OBJECTIVE: The aim of this study was to perform a biochemical, functional and histopathological investigation of the potential protective effect of eugenol against cisplatin-induced ototoxicity.
METHODS: The study was performed with 24 female Sprague Dawley rats. Distortion product otoacoustic emissions tests were performed on all animals, which were randomized into four equal groups. A single intraperitoneal dose of 15mg/kg cisplatin was administered to cisplatin group, while the eugenol group received 100mg/kg eugenol intraperitoneal for five consecutive days. 100mg/kg eugenol was administered to cisplatin+eugenol group for 5 days. On the third day, these rats were received a single dose of 15mg/kg cisplatin. The control group was given 8mL/kg/day intraperitoneal saline solution for five days. The distortion product otoacoustic emissions test was repeated 24h after the final drug administration. All animals were sacrificed, and the cochleas were subsequently used for biochemical and histopathological examinations.
RESULTS: Cisplatin caused oxidative stress in the cochlea, impaired the cochlear structure and significantly reduced signal noise ratio levels. Administration of eugenol together with cisplatin reversed these effects and provided functional, biochemical and histopathological protection.
CONCLUSION: The study findings represent the first indication in the literature that eugenol may protect against ototoxicity by raising levels of antioxidant enzymes and lowering those of oxidant parameters.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
Brazilian journal of otorhinolaryngology - 85(2019), 6 vom: 19. Nov., Seite 766-773 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sakat, Muhammed Sedat [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.12.2019 Date Revised 10.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bjorl.2018.07.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM287653749 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM287653749 | ||
| 003 | DE-627 | ||
| 005 | 20231225054510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bjorl.2018.07.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0958.xml |
| 035 | |a (DE-627)NLM287653749 | ||
| 035 | |a (NLM)30126770 | ||
| 035 | |a (PII)S1808-8694(18)30233-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sakat, Muhammed Sedat |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effectiveness of eugenol against cisplatin-induced ototoxicity |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2019 | ||
| 500 | |a Date Revised 10.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. All rights reserved. | ||
| 520 | |a INTRODUCTION: Ototoxicity refers to cellular damage or function impairment developing in the inner ear in association with any therapeutic agent or chemical substance, and still represents the principal side-effect restricting the use of cisplatin | ||
| 520 | |a OBJECTIVE: The aim of this study was to perform a biochemical, functional and histopathological investigation of the potential protective effect of eugenol against cisplatin-induced ototoxicity | ||
| 520 | |a METHODS: The study was performed with 24 female Sprague Dawley rats. Distortion product otoacoustic emissions tests were performed on all animals, which were randomized into four equal groups. A single intraperitoneal dose of 15mg/kg cisplatin was administered to cisplatin group, while the eugenol group received 100mg/kg eugenol intraperitoneal for five consecutive days. 100mg/kg eugenol was administered to cisplatin+eugenol group for 5 days. On the third day, these rats were received a single dose of 15mg/kg cisplatin. The control group was given 8mL/kg/day intraperitoneal saline solution for five days. The distortion product otoacoustic emissions test was repeated 24h after the final drug administration. All animals were sacrificed, and the cochleas were subsequently used for biochemical and histopathological examinations | ||
| 520 | |a RESULTS: Cisplatin caused oxidative stress in the cochlea, impaired the cochlear structure and significantly reduced signal noise ratio levels. Administration of eugenol together with cisplatin reversed these effects and provided functional, biochemical and histopathological protection | ||
| 520 | |a CONCLUSION: The study findings represent the first indication in the literature that eugenol may protect against ototoxicity by raising levels of antioxidant enzymes and lowering those of oxidant parameters | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 8-Hidroxi-2′-deoxiguanosina | |
| 650 | 4 | |a 8-Hydroxy-2′-deoxyguanosine | |
| 650 | 4 | |a Cisplatin-induced ototoxicity | |
| 650 | 4 | |a DPOAE | |
| 650 | 4 | |a EOAPD | |
| 650 | 4 | |a Estresse oxidativo | |
| 650 | 4 | |a Eugenol | |
| 650 | 4 | |a Ototoxicidade induzida pela cisplatina | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Eugenol |2 NLM | |
| 650 | 7 | |a 3T8H1794QW |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Kilic, Korhan |e verfasserin |4 aut | |
| 700 | 1 | |a Akdemir, Fazile Nur Ekinci |e verfasserin |4 aut | |
| 700 | 1 | |a Yildirim, Serkan |e verfasserin |4 aut | |
| 700 | 1 | |a Eser, Gizem |e verfasserin |4 aut | |
| 700 | 1 | |a Kiziltunc, Ahmet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brazilian journal of otorhinolaryngology |d 2005 |g 85(2019), 6 vom: 19. Nov., Seite 766-773 |w (DE-627)NLM160421748 |x 1808-8686 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2019 |g number:6 |g day:19 |g month:11 |g pages:766-773 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bjorl.2018.07.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2019 |e 6 |b 19 |c 11 |h 766-773 | ||